Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Артериальная гипертония и деменция: потенциал антагониста кальция нитрендипина
Артериальная гипертония и деменция: потенциал антагониста кальция нитрендипина
Котовская Ю.В., Остапенко В.С., Ткачева О.Н. Артериальная гипертония и деменция: потенциал антагониста кальция нитрендипина. Consilium Medicum. 2017; 19 (5): 8–13.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Проблема деменции имеет очень важное медицинское, социальное и экономическое значение ввиду старения популяции. В представленном обзоре отражено место артериальной гипертонии как фактора риска деменции и методы выявления деменции в реальной клинической практике. Анализируется неоднозначная взаимосвязь уровня артериального давления с развитием и прогрессированием различных типов деменции. Приведены данные об эффективности современной антигипертензивной терапии для профилактики деменции с фокусом на потенциале антагониста кальция нитрендипина, показавшего свой церебропротективный потенциал в ряде экспериментальных исследований и крупномасштабном рандомизированном плацебо-контролируемом исследовании Syst-Eur.
Ключевые слова: артериальная гипертония, деменция, антигипертензивная терапия, нитрендипин.
Key words: arterial hypertension, dementia, antihypertensive therapy, nitrendipine.
Ключевые слова: артериальная гипертония, деменция, антигипертензивная терапия, нитрендипин.
________________________________________________
Key words: arterial hypertension, dementia, antihypertensive therapy, nitrendipine.
Полный текст
Список литературы
1. Wimo A, Winblad B, Aguero-Torres H, von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 2003; 17 (2): 63–7.
2. Hendrie HC. Epidemiology of dementia and Alzheimer’s disease. Am J Geriatr Psychiatry 1998; 6 (2 Suppl. 1): S3–18.
3. Ruitenberg A, Ott A, van Swieten JC et al. Incidence of dementia: does gender make a difference? Neurobiol Aging 2001; 22 (4): 575–80.
4. Roman GC. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am 2002; 86 (3): 477–99.
5. Shehab A, Abdulle A. Cognitive and autonomic dysfunction measures in normal controls, white coat and borderline hypertension. BMC Cardiovasc Disord 2011; 11: 3.
6. Mahoney JR, Verghese J, Goldin Y et al. Alerting, orienting, and executive attention in older adults. J Int Neuropsychol Soc 2010; 16 (5): 877–89.
7. Richmond R, Law J, Kay-Lambkin F. Higher blood pressure associated with higher cognition and functionality among centenarians in Australia. Am J Hypertens 2011; 24 (3): 299–303.
8. Szewieczek J, Dulawa J, Gminski J et al. Better cognitive and physical performance is associated with higher blood pressure in centenarians. J Nutr Health Aging 2011; 15 (8): 618–22.
9. Skoog I, Lernfelt B, Landahl S et al. 15year longitudinal study of blood pressure and dementia. Lancet 1996; 347 (9009): 1130.
10. Elias MF, Elias PK, Sullivan LM et al. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord 2003; 27 (2): 260–8.
11. Goldstein FC, Levey AI, Steenland NK. High blood pressure and cognitive decline in mild cognitive impairment. J Am Geriatr Soc 2013; 61 (1): 67–73.
12. Launer LJ, Hughes T, Yu B et al. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/Honolulu Asia Aging Study. Hypertension 2010; 55 (6): 1352–9.
13. Reijmer YD, van den Berg E, Dekker JM et al. Development of vascular risk factors over 15 years in relation to cognition: the Hoorn Study. J Am Geriatr Soc 2012; 60 (8): 1426–33.
14. Hebert LE, Scherr PA, Bennett DA et al. Blood pressure and late-life cognitive function change: a biracial longitudinal population study. Neurology 2004; 62 (11): 2021–4.
15. Tervo S, Kivipelto M, Hanninen T et al. Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. Dement Geriatr Cogn Disord 2004; 17 (3): 196–203.
16. Bohannon AD, Fillenbaum GG, Pieper CF et al. Relationship of race/ethnicity and blood pressure to change in cognitive function. J Am Geriatr Soc 2002; 50 (3): 424–9.
17. Xu W, Tan L, Wang H-F et al. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2015; 86 (12): 1299–306.
18. Hajjar I, Zhao P, Alsop D, Novak V. Hypertension and cerebral vasoreactivity: a continuous arterial spin labeling magnetic resonance imaging study. Hypertension 2010; 56 (5): 859–64.
19. Qiu C, Winblad B, Viitanen M, Fratiglioni L. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: a community-based, longitudinal study. Stroke 2003; 34 (3): 594–9.
20. Nation DA, Delano-Wood L, Bangen KJ et al. Antemortem pulse pressure elevation predicts cerebrovascular disease in autopsy-confirmed Alzheimer’s disease. J Alzheimers Dis 2012; 30 (3): 595–603.
21. Rabkin SW, Jarvie G. Comparison of vascular stiffness in vascular dementia, Alzheimer dementia and cognitive impairment. Blood Press 2011; 20 (5): 274–83.
22. Diz DI, Lewis K. Dahl memorial lecture: the renin-angiotensin system and aging. Hypertension 2008; 52 (1): 37–43.
23. Gustafson DR, Melchior L, Eriksson E et al. The ACE insertion deletion polymorphism relates to dementia by metabolic phenotype, APOEepsilon4, and age of dementia onset. Neurobiol Aging 2010; 31 (6): 910–6.
24. Jennings JR, Heim AF. From brain to beh * avior: hypertension’s modulation of cognition and affect. Int J Hypertens 2012; 2012: 701385.
25. Gorelick PB, Scuteri A, Black SE et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42 (9): 2672–713.
26. Bosch J, Lonn E, Yusuf S; HOPE-3 Investigators. The effect of blood pressure and cholesterol lowering on cognition. Program and abstracts of the American Heart Association 2016 Scientific Sessions; November 13, 2016; New Orleans, Louisiana. Abstract LBCT-01.
27. Staessen JA, Thijs L, Richart T et al. Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension 2011; 57: e6–7.
28. Chang-Quan H, Hui W, Chao-Min W et al. The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies. Int J Clin Pract 2011; 65 (12): 1295–305.
29. Petrella RJ, Shlyakhto E, Konradi AO et al. Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension: a retrospective subgroup analysis of the Observational Study on Cognitive Function and SBP Reduction (OSCAR) study. J Clin Hypertens (Greenwich) 2012; 14 (2): 78–84.
30. Kume K, Hanyu H, Sakurai H et al. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer’s disease. Geriatr Gerontol Int 2012; 12 (2): 207–14.
31. Chiu WC, Ho WC, Lin MH et al. Angiotensin receptor blockers reduce the risk of dementia. J Hypertens 2014, 32: 938–47.
32. Manisty CH, Hughes AD. Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. Br J Clin Pharmacol 2012; 75 (1): 79–92.
33. Pase MP, Beiser A, Himali JJ et al. Aortic Stiffness and the Risk of Incident Mild Cognitive Impairment and Dementia. Stroke 2016; 47: 2256–61.
34. Mattace-Raso F, van der Cammen TJM, Hofman A et al. Arterial Stiffness and Risk of Coronary Heart Disease and Stroke. The Rotterdam Study. Circulation 2006; 113: 657–63.
35. Toescu EC, Xiong J. Metabolic substrates of neuronal aging. Ann N Y Acad Sci 2004; 1019: 19–23.
36. Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D. Selective dihydropyiridine compounds facilitate the clearance of beta-amyloid across the blood-brain barrier. Eur J Pharmacol.2011; 659: 124–9.
37. Paris D, Bachmeier C, Patel N et al. Selective antihypertensive dihydropyridines lower abeta accumulation by targeting both the production and the clearance of abeta across the blood-brain barrier. Mol Med 2011; 17: 149–62.
38. Corbett A, Pickett J, Burns A et al. Drug repositioning for Alzheimer’s disease. Nature Reviews Drug Discovery 2012; 11: 833–46.
39. Watfa G, Rossignol P, Kearney-Schwartz A et al. Use of calcium channel blockers is associated with better cognitive performance in older hypertensive patients with subjective memory complaints. J Hypertens 2010; 28 (12): 2485–93.
40. Trompet S et al. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol Aging 2008; 29 (2): 306–8.
41. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment or older patients with isolated systolic hypertension. Lancet 1997; 350: 757–64.
42. Thijs L, Staessen JA, Beleva S et al. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Curr Control Trials Cardiovasc Med 2001; 2: 298–306.
43. Tuomilehto J et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677–84.
44. Liu L, Wang JG, Gong L et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertension 1998; 16: 1823–9.
45. Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352 (9137): 1347–51.
2. Hendrie HC. Epidemiology of dementia and Alzheimer’s disease. Am J Geriatr Psychiatry 1998; 6 (2 Suppl. 1): S3–18.
3. Ruitenberg A, Ott A, van Swieten JC et al. Incidence of dementia: does gender make a difference? Neurobiol Aging 2001; 22 (4): 575–80.
4. Roman GC. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am 2002; 86 (3): 477–99.
5. Shehab A, Abdulle A. Cognitive and autonomic dysfunction measures in normal controls, white coat and borderline hypertension. BMC Cardiovasc Disord 2011; 11: 3.
6. Mahoney JR, Verghese J, Goldin Y et al. Alerting, orienting, and executive attention in older adults. J Int Neuropsychol Soc 2010; 16 (5): 877–89.
7. Richmond R, Law J, Kay-Lambkin F. Higher blood pressure associated with higher cognition and functionality among centenarians in Australia. Am J Hypertens 2011; 24 (3): 299–303.
8. Szewieczek J, Dulawa J, Gminski J et al. Better cognitive and physical performance is associated with higher blood pressure in centenarians. J Nutr Health Aging 2011; 15 (8): 618–22.
9. Skoog I, Lernfelt B, Landahl S et al. 15year longitudinal study of blood pressure and dementia. Lancet 1996; 347 (9009): 1130.
10. Elias MF, Elias PK, Sullivan LM et al. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord 2003; 27 (2): 260–8.
11. Goldstein FC, Levey AI, Steenland NK. High blood pressure and cognitive decline in mild cognitive impairment. J Am Geriatr Soc 2013; 61 (1): 67–73.
12. Launer LJ, Hughes T, Yu B et al. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/Honolulu Asia Aging Study. Hypertension 2010; 55 (6): 1352–9.
13. Reijmer YD, van den Berg E, Dekker JM et al. Development of vascular risk factors over 15 years in relation to cognition: the Hoorn Study. J Am Geriatr Soc 2012; 60 (8): 1426–33.
14. Hebert LE, Scherr PA, Bennett DA et al. Blood pressure and late-life cognitive function change: a biracial longitudinal population study. Neurology 2004; 62 (11): 2021–4.
15. Tervo S, Kivipelto M, Hanninen T et al. Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. Dement Geriatr Cogn Disord 2004; 17 (3): 196–203.
16. Bohannon AD, Fillenbaum GG, Pieper CF et al. Relationship of race/ethnicity and blood pressure to change in cognitive function. J Am Geriatr Soc 2002; 50 (3): 424–9.
17. Xu W, Tan L, Wang H-F et al. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2015; 86 (12): 1299–306.
18. Hajjar I, Zhao P, Alsop D, Novak V. Hypertension and cerebral vasoreactivity: a continuous arterial spin labeling magnetic resonance imaging study. Hypertension 2010; 56 (5): 859–64.
19. Qiu C, Winblad B, Viitanen M, Fratiglioni L. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: a community-based, longitudinal study. Stroke 2003; 34 (3): 594–9.
20. Nation DA, Delano-Wood L, Bangen KJ et al. Antemortem pulse pressure elevation predicts cerebrovascular disease in autopsy-confirmed Alzheimer’s disease. J Alzheimers Dis 2012; 30 (3): 595–603.
21. Rabkin SW, Jarvie G. Comparison of vascular stiffness in vascular dementia, Alzheimer dementia and cognitive impairment. Blood Press 2011; 20 (5): 274–83.
22. Diz DI, Lewis K. Dahl memorial lecture: the renin-angiotensin system and aging. Hypertension 2008; 52 (1): 37–43.
23. Gustafson DR, Melchior L, Eriksson E et al. The ACE insertion deletion polymorphism relates to dementia by metabolic phenotype, APOEepsilon4, and age of dementia onset. Neurobiol Aging 2010; 31 (6): 910–6.
24. Jennings JR, Heim AF. From brain to beh * avior: hypertension’s modulation of cognition and affect. Int J Hypertens 2012; 2012: 701385.
25. Gorelick PB, Scuteri A, Black SE et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42 (9): 2672–713.
26. Bosch J, Lonn E, Yusuf S; HOPE-3 Investigators. The effect of blood pressure and cholesterol lowering on cognition. Program and abstracts of the American Heart Association 2016 Scientific Sessions; November 13, 2016; New Orleans, Louisiana. Abstract LBCT-01.
27. Staessen JA, Thijs L, Richart T et al. Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension 2011; 57: e6–7.
28. Chang-Quan H, Hui W, Chao-Min W et al. The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies. Int J Clin Pract 2011; 65 (12): 1295–305.
29. Petrella RJ, Shlyakhto E, Konradi AO et al. Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension: a retrospective subgroup analysis of the Observational Study on Cognitive Function and SBP Reduction (OSCAR) study. J Clin Hypertens (Greenwich) 2012; 14 (2): 78–84.
30. Kume K, Hanyu H, Sakurai H et al. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer’s disease. Geriatr Gerontol Int 2012; 12 (2): 207–14.
31. Chiu WC, Ho WC, Lin MH et al. Angiotensin receptor blockers reduce the risk of dementia. J Hypertens 2014, 32: 938–47.
32. Manisty CH, Hughes AD. Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. Br J Clin Pharmacol 2012; 75 (1): 79–92.
33. Pase MP, Beiser A, Himali JJ et al. Aortic Stiffness and the Risk of Incident Mild Cognitive Impairment and Dementia. Stroke 2016; 47: 2256–61.
34. Mattace-Raso F, van der Cammen TJM, Hofman A et al. Arterial Stiffness and Risk of Coronary Heart Disease and Stroke. The Rotterdam Study. Circulation 2006; 113: 657–63.
35. Toescu EC, Xiong J. Metabolic substrates of neuronal aging. Ann N Y Acad Sci 2004; 1019: 19–23.
36. Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D. Selective dihydropyiridine compounds facilitate the clearance of beta-amyloid across the blood-brain barrier. Eur J Pharmacol.2011; 659: 124–9.
37. Paris D, Bachmeier C, Patel N et al. Selective antihypertensive dihydropyridines lower abeta accumulation by targeting both the production and the clearance of abeta across the blood-brain barrier. Mol Med 2011; 17: 149–62.
38. Corbett A, Pickett J, Burns A et al. Drug repositioning for Alzheimer’s disease. Nature Reviews Drug Discovery 2012; 11: 833–46.
39. Watfa G, Rossignol P, Kearney-Schwartz A et al. Use of calcium channel blockers is associated with better cognitive performance in older hypertensive patients with subjective memory complaints. J Hypertens 2010; 28 (12): 2485–93.
40. Trompet S et al. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol Aging 2008; 29 (2): 306–8.
41. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment or older patients with isolated systolic hypertension. Lancet 1997; 350: 757–64.
42. Thijs L, Staessen JA, Beleva S et al. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Curr Control Trials Cardiovasc Med 2001; 2: 298–306.
43. Tuomilehto J et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677–84.
44. Liu L, Wang JG, Gong L et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertension 1998; 16: 1823–9.
45. Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352 (9137): 1347–51.
2. Hendrie HC. Epidemiology of dementia and Alzheimer’s disease. Am J Geriatr Psychiatry 1998; 6 (2 Suppl. 1): S3–18.
3. Ruitenberg A, Ott A, van Swieten JC et al. Incidence of dementia: does gender make a difference? Neurobiol Aging 2001; 22 (4): 575–80.
4. Roman GC. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am 2002; 86 (3): 477–99.
5. Shehab A, Abdulle A. Cognitive and autonomic dysfunction measures in normal controls, white coat and borderline hypertension. BMC Cardiovasc Disord 2011; 11: 3.
6. Mahoney JR, Verghese J, Goldin Y et al. Alerting, orienting, and executive attention in older adults. J Int Neuropsychol Soc 2010; 16 (5): 877–89.
7. Richmond R, Law J, Kay-Lambkin F. Higher blood pressure associated with higher cognition and functionality among centenarians in Australia. Am J Hypertens 2011; 24 (3): 299–303.
8. Szewieczek J, Dulawa J, Gminski J et al. Better cognitive and physical performance is associated with higher blood pressure in centenarians. J Nutr Health Aging 2011; 15 (8): 618–22.
9. Skoog I, Lernfelt B, Landahl S et al. 15year longitudinal study of blood pressure and dementia. Lancet 1996; 347 (9009): 1130.
10. Elias MF, Elias PK, Sullivan LM et al. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord 2003; 27 (2): 260–8.
11. Goldstein FC, Levey AI, Steenland NK. High blood pressure and cognitive decline in mild cognitive impairment. J Am Geriatr Soc 2013; 61 (1): 67–73.
12. Launer LJ, Hughes T, Yu B et al. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/Honolulu Asia Aging Study. Hypertension 2010; 55 (6): 1352–9.
13. Reijmer YD, van den Berg E, Dekker JM et al. Development of vascular risk factors over 15 years in relation to cognition: the Hoorn Study. J Am Geriatr Soc 2012; 60 (8): 1426–33.
14. Hebert LE, Scherr PA, Bennett DA et al. Blood pressure and late-life cognitive function change: a biracial longitudinal population study. Neurology 2004; 62 (11): 2021–4.
15. Tervo S, Kivipelto M, Hanninen T et al. Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. Dement Geriatr Cogn Disord 2004; 17 (3): 196–203.
16. Bohannon AD, Fillenbaum GG, Pieper CF et al. Relationship of race/ethnicity and blood pressure to change in cognitive function. J Am Geriatr Soc 2002; 50 (3): 424–9.
17. Xu W, Tan L, Wang H-F et al. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2015; 86 (12): 1299–306.
18. Hajjar I, Zhao P, Alsop D, Novak V. Hypertension and cerebral vasoreactivity: a continuous arterial spin labeling magnetic resonance imaging study. Hypertension 2010; 56 (5): 859–64.
19. Qiu C, Winblad B, Viitanen M, Fratiglioni L. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: a community-based, longitudinal study. Stroke 2003; 34 (3): 594–9.
20. Nation DA, Delano-Wood L, Bangen KJ et al. Antemortem pulse pressure elevation predicts cerebrovascular disease in autopsy-confirmed Alzheimer’s disease. J Alzheimers Dis 2012; 30 (3): 595–603.
21. Rabkin SW, Jarvie G. Comparison of vascular stiffness in vascular dementia, Alzheimer dementia and cognitive impairment. Blood Press 2011; 20 (5): 274–83.
22. Diz DI, Lewis K. Dahl memorial lecture: the renin-angiotensin system and aging. Hypertension 2008; 52 (1): 37–43.
23. Gustafson DR, Melchior L, Eriksson E et al. The ACE insertion deletion polymorphism relates to dementia by metabolic phenotype, APOEepsilon4, and age of dementia onset. Neurobiol Aging 2010; 31 (6): 910–6.
24. Jennings JR, Heim AF. From brain to beh * avior: hypertension’s modulation of cognition and affect. Int J Hypertens 2012; 2012: 701385.
25. Gorelick PB, Scuteri A, Black SE et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42 (9): 2672–713.
26. Bosch J, Lonn E, Yusuf S; HOPE-3 Investigators. The effect of blood pressure and cholesterol lowering on cognition. Program and abstracts of the American Heart Association 2016 Scientific Sessions; November 13, 2016; New Orleans, Louisiana. Abstract LBCT-01.
27. Staessen JA, Thijs L, Richart T et al. Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension 2011; 57: e6–7.
28. Chang-Quan H, Hui W, Chao-Min W et al. The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies. Int J Clin Pract 2011; 65 (12): 1295–305.
29. Petrella RJ, Shlyakhto E, Konradi AO et al. Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension: a retrospective subgroup analysis of the Observational Study on Cognitive Function and SBP Reduction (OSCAR) study. J Clin Hypertens (Greenwich) 2012; 14 (2): 78–84.
30. Kume K, Hanyu H, Sakurai H et al. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer’s disease. Geriatr Gerontol Int 2012; 12 (2): 207–14.
31. Chiu WC, Ho WC, Lin MH et al. Angiotensin receptor blockers reduce the risk of dementia. J Hypertens 2014, 32: 938–47.
32. Manisty CH, Hughes AD. Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. Br J Clin Pharmacol 2012; 75 (1): 79–92.
33. Pase MP, Beiser A, Himali JJ et al. Aortic Stiffness and the Risk of Incident Mild Cognitive Impairment and Dementia. Stroke 2016; 47: 2256–61.
34. Mattace-Raso F, van der Cammen TJM, Hofman A et al. Arterial Stiffness and Risk of Coronary Heart Disease and Stroke. The Rotterdam Study. Circulation 2006; 113: 657–63.
35. Toescu EC, Xiong J. Metabolic substrates of neuronal aging. Ann N Y Acad Sci 2004; 1019: 19–23.
36. Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D. Selective dihydropyiridine compounds facilitate the clearance of beta-amyloid across the blood-brain barrier. Eur J Pharmacol.2011; 659: 124–9.
37. Paris D, Bachmeier C, Patel N et al. Selective antihypertensive dihydropyridines lower abeta accumulation by targeting both the production and the clearance of abeta across the blood-brain barrier. Mol Med 2011; 17: 149–62.
38. Corbett A, Pickett J, Burns A et al. Drug repositioning for Alzheimer’s disease. Nature Reviews Drug Discovery 2012; 11: 833–46.
39. Watfa G, Rossignol P, Kearney-Schwartz A et al. Use of calcium channel blockers is associated with better cognitive performance in older hypertensive patients with subjective memory complaints. J Hypertens 2010; 28 (12): 2485–93.
40. Trompet S et al. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol Aging 2008; 29 (2): 306–8.
41. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment or older patients with isolated systolic hypertension. Lancet 1997; 350: 757–64.
42. Thijs L, Staessen JA, Beleva S et al. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Curr Control Trials Cardiovasc Med 2001; 2: 298–306.
43. Tuomilehto J et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677–84.
44. Liu L, Wang JG, Gong L et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertension 1998; 16: 1823–9.
45. Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352 (9137): 1347–51.
________________________________________________
2. Hendrie HC. Epidemiology of dementia and Alzheimer’s disease. Am J Geriatr Psychiatry 1998; 6 (2 Suppl. 1): S3–18.
3. Ruitenberg A, Ott A, van Swieten JC et al. Incidence of dementia: does gender make a difference? Neurobiol Aging 2001; 22 (4): 575–80.
4. Roman GC. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am 2002; 86 (3): 477–99.
5. Shehab A, Abdulle A. Cognitive and autonomic dysfunction measures in normal controls, white coat and borderline hypertension. BMC Cardiovasc Disord 2011; 11: 3.
6. Mahoney JR, Verghese J, Goldin Y et al. Alerting, orienting, and executive attention in older adults. J Int Neuropsychol Soc 2010; 16 (5): 877–89.
7. Richmond R, Law J, Kay-Lambkin F. Higher blood pressure associated with higher cognition and functionality among centenarians in Australia. Am J Hypertens 2011; 24 (3): 299–303.
8. Szewieczek J, Dulawa J, Gminski J et al. Better cognitive and physical performance is associated with higher blood pressure in centenarians. J Nutr Health Aging 2011; 15 (8): 618–22.
9. Skoog I, Lernfelt B, Landahl S et al. 15year longitudinal study of blood pressure and dementia. Lancet 1996; 347 (9009): 1130.
10. Elias MF, Elias PK, Sullivan LM et al. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord 2003; 27 (2): 260–8.
11. Goldstein FC, Levey AI, Steenland NK. High blood pressure and cognitive decline in mild cognitive impairment. J Am Geriatr Soc 2013; 61 (1): 67–73.
12. Launer LJ, Hughes T, Yu B et al. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/Honolulu Asia Aging Study. Hypertension 2010; 55 (6): 1352–9.
13. Reijmer YD, van den Berg E, Dekker JM et al. Development of vascular risk factors over 15 years in relation to cognition: the Hoorn Study. J Am Geriatr Soc 2012; 60 (8): 1426–33.
14. Hebert LE, Scherr PA, Bennett DA et al. Blood pressure and late-life cognitive function change: a biracial longitudinal population study. Neurology 2004; 62 (11): 2021–4.
15. Tervo S, Kivipelto M, Hanninen T et al. Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. Dement Geriatr Cogn Disord 2004; 17 (3): 196–203.
16. Bohannon AD, Fillenbaum GG, Pieper CF et al. Relationship of race/ethnicity and blood pressure to change in cognitive function. J Am Geriatr Soc 2002; 50 (3): 424–9.
17. Xu W, Tan L, Wang H-F et al. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2015; 86 (12): 1299–306.
18. Hajjar I, Zhao P, Alsop D, Novak V. Hypertension and cerebral vasoreactivity: a continuous arterial spin labeling magnetic resonance imaging study. Hypertension 2010; 56 (5): 859–64.
19. Qiu C, Winblad B, Viitanen M, Fratiglioni L. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: a community-based, longitudinal study. Stroke 2003; 34 (3): 594–9.
20. Nation DA, Delano-Wood L, Bangen KJ et al. Antemortem pulse pressure elevation predicts cerebrovascular disease in autopsy-confirmed Alzheimer’s disease. J Alzheimers Dis 2012; 30 (3): 595–603.
21. Rabkin SW, Jarvie G. Comparison of vascular stiffness in vascular dementia, Alzheimer dementia and cognitive impairment. Blood Press 2011; 20 (5): 274–83.
22. Diz DI, Lewis K. Dahl memorial lecture: the renin-angiotensin system and aging. Hypertension 2008; 52 (1): 37–43.
23. Gustafson DR, Melchior L, Eriksson E et al. The ACE insertion deletion polymorphism relates to dementia by metabolic phenotype, APOEepsilon4, and age of dementia onset. Neurobiol Aging 2010; 31 (6): 910–6.
24. Jennings JR, Heim AF. From brain to beh * avior: hypertension’s modulation of cognition and affect. Int J Hypertens 2012; 2012: 701385.
25. Gorelick PB, Scuteri A, Black SE et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42 (9): 2672–713.
26. Bosch J, Lonn E, Yusuf S; HOPE-3 Investigators. The effect of blood pressure and cholesterol lowering on cognition. Program and abstracts of the American Heart Association 2016 Scientific Sessions; November 13, 2016; New Orleans, Louisiana. Abstract LBCT-01.
27. Staessen JA, Thijs L, Richart T et al. Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension 2011; 57: e6–7.
28. Chang-Quan H, Hui W, Chao-Min W et al. The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies. Int J Clin Pract 2011; 65 (12): 1295–305.
29. Petrella RJ, Shlyakhto E, Konradi AO et al. Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension: a retrospective subgroup analysis of the Observational Study on Cognitive Function and SBP Reduction (OSCAR) study. J Clin Hypertens (Greenwich) 2012; 14 (2): 78–84.
30. Kume K, Hanyu H, Sakurai H et al. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer’s disease. Geriatr Gerontol Int 2012; 12 (2): 207–14.
31. Chiu WC, Ho WC, Lin MH et al. Angiotensin receptor blockers reduce the risk of dementia. J Hypertens 2014, 32: 938–47.
32. Manisty CH, Hughes AD. Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. Br J Clin Pharmacol 2012; 75 (1): 79–92.
33. Pase MP, Beiser A, Himali JJ et al. Aortic Stiffness and the Risk of Incident Mild Cognitive Impairment and Dementia. Stroke 2016; 47: 2256–61.
34. Mattace-Raso F, van der Cammen TJM, Hofman A et al. Arterial Stiffness and Risk of Coronary Heart Disease and Stroke. The Rotterdam Study. Circulation 2006; 113: 657–63.
35. Toescu EC, Xiong J. Metabolic substrates of neuronal aging. Ann N Y Acad Sci 2004; 1019: 19–23.
36. Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D. Selective dihydropyiridine compounds facilitate the clearance of beta-amyloid across the blood-brain barrier. Eur J Pharmacol.2011; 659: 124–9.
37. Paris D, Bachmeier C, Patel N et al. Selective antihypertensive dihydropyridines lower abeta accumulation by targeting both the production and the clearance of abeta across the blood-brain barrier. Mol Med 2011; 17: 149–62.
38. Corbett A, Pickett J, Burns A et al. Drug repositioning for Alzheimer’s disease. Nature Reviews Drug Discovery 2012; 11: 833–46.
39. Watfa G, Rossignol P, Kearney-Schwartz A et al. Use of calcium channel blockers is associated with better cognitive performance in older hypertensive patients with subjective memory complaints. J Hypertens 2010; 28 (12): 2485–93.
40. Trompet S et al. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol Aging 2008; 29 (2): 306–8.
41. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment or older patients with isolated systolic hypertension. Lancet 1997; 350: 757–64.
42. Thijs L, Staessen JA, Beleva S et al. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Curr Control Trials Cardiovasc Med 2001; 2: 298–306.
43. Tuomilehto J et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677–84.
44. Liu L, Wang JG, Gong L et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertension 1998; 16: 1823–9.
45. Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352 (9137): 1347–51.
Авторы
Ю.В.Котовская*1,2, В.С.Остапенко2, О.Н.Ткачева2
1 ФГАОУ ВО «Российский университет дружбы народов». 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6;
2 «Российский геронтологический научно-клинический центр» ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова». 129226, Россия, Москва, ул. Леонова, д. 16а
*kotovskaya@bk.ru
1 People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaya, d. 6;
2 N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 129226, Russian Federation, Moscow, ul. Leonova, d. 16a
*kotovskaya@bk.ru
1 ФГАОУ ВО «Российский университет дружбы народов». 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6;
2 «Российский геронтологический научно-клинический центр» ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова». 129226, Россия, Москва, ул. Леонова, д. 16а
*kotovskaya@bk.ru
________________________________________________
1 People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaya, d. 6;
2 N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 129226, Russian Federation, Moscow, ul. Leonova, d. 16a
*kotovskaya@bk.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.